Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Steroid shot before angioplasty may limit heart damage

NCT ID NCT05462730

Disease control Sponsor: Thomas Engstrom Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving a single, strong dose of steroids to people right after a major heart attack (STEMI) could reduce the amount of heart muscle that gets permanently damaged. The steroid was given before the standard emergency procedure to open the blocked artery. The trial involved 530 adults with chest pain lasting less than 12 hours. The main goal was to measure the final size of the heart injury using MRI scans.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

530 people

The number who actually took part.

Started

Nov 2022

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18 years including fertile women (It is not possible to perform a pregnancy test (HCG urine test) in the pre-hospital setting. However, methylprednisolone is not contraindicated in pregnant women). 2. Acute onset of chest pain with \< 12 hours duration. 3. STEMI as characterized on electrocardiogram (ECG) by one of the following: 1\) at least two contiguous leads with ST-segment elevation ≥2.5 mm in men \< 40 years, ≥2 mm in men ≥40 years, or ≥1.5 mm in women in leads V2-V3 and/or ≥1 mm in the other leads, 2) presumed new left bundle branch block with ≥1 mm concordant ST-segment ele-vation in leads with a positive QRS complex, or concordant ST-segment depression ≥1 mm in V1-V3, or discordant ST-segment elevation ≥5 mm in leads with a negative QRS complex, 3) Isolated ST depression ≥0.5 mm in leads V1-V3 and ST-segment elevation (≥0.5 mm) in posterior chest wall leads V7-V9 indicating posterior acute myocardial infarc-tion (AMI), 4) ST-segment depression ≥1 mm in eight or more surface leads, coupled with ST-segment elevation in aVR and/or V1 suggesting left main-, or left main equivalent- coronary obstruction. Exclusion Criteria: 1. Presentation with cardiac arrest (out of hospital cardiac arrest (OHCA)). 2. Time from symptoms onset to primary PCI \> 12 hours. 3. Known allergy to glucocorticoid or known mental illness with maniac or psychotic episodes. 4. Patients with previous acute myocardial infarction (AMI) in the assumed culprit artery. 5. Previous coronary artery bypass graft (CABG). 6. Unable to read and understand Danish.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Inflammatory response are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Inflammation inflammatory disease ischemia reperfusion injury Myocardial Reperfusion Injury ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Inflammatory response Myocardial injury Myocardial reperfusion injury ST elevation myocardial infarction

Contacts and locations

Locations

  • Heart Center, Rigshospitalet

    Copenhagen, Capital Region, 2100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.